AGS-003: Phase III ongoing

An IDMC recommended continuation of the open-label, international Phase III ADAPT trial comparing AGS-003 plus Sutent sunitinib vs. Sutent alone in 462 patients. Patients are receiving >=8 intradermal injections of AGS-003 in the first year, followed by quarterly boosters. ...